Gurujoe
Nov 4, 5:44 PM
$CATX | Lantheus Overhang, Upcoming Clinical Catalysts & Potential Re-Rating
At ~
$0.90, CATX’s valuation appears increasingly disconnected from its clinical pipeline, reported cash position and approaching catalysts.
The decline in Cohort 2 ORR from 43% to 33% created legitimate headwinds. However, Cohort 3 delivered a 50% ORR (including unconfirmed responses), 95% DCR and encouraging early safety. Pooled 18-month PFS reached 72%. Responses continue to mature after treatment completion.
The larger valuation overhang may be Lantheus.
Lantheus has disclosed substantial CATX share sales. Its pending acquisition by Curium introduces a potential strategic conflict: Curium already has BEXLUTRY, a competing Lu-177 GEP-NET therapy.
Meanwhile, Lantheus’s previously disclosed VMT-α-NET licensing option creates uncertainty around CATX’s ability to pursue new strategic partnerships.
This combination may explain why institutional buyers are hesitant to accumulate aggressively despite the valuation discount.
Upcoming catalysts:
* Nov. 5 — NANETS: Mayo Clinic oral presentation of VMT-α-NET Cohorts 1–3. Watch response durability, PFS, SSTR2 selection and renal safety.
* Nov. 6 — SITC: VMT01 melanoma poster covering monotherapy and nivolumab combination. Potential validation of CATX’s second clinical platform.
* Nov. 20 — ENA: Additional VMT-α-NET clinical presentation, offering another opportunity to evaluate efficacy and safety.
* Q3 results: Potential clarification of cash runway, Lantheus’s licensing-option status, strategic flexibility and Phase 3 preparations.
* Year-end: FDA regulatory alignment and Phase 3 readiness updates could further de-risk VMT-α-NET.
Q3 could be particularly consequential. Confirmation that Lantheus’s licensing restrictions have expired or been relinquished, combined with evidence that its selling overhang is resolving, could materially improve investor confidence and restore strategic optionality.
Neither development is confirmed, and Lantheus’s ownership changes may require separate SEC disclosures.
CATX’s last reported cash and short-term investments were approximately
$237M at June 30, substantially above its implied market capitalization at today’s price.
My thesis: Clinical disappointment may have initiated the selloff, but strategic uncertainty and institutional supply could be magnifying it. Removing those overhangs while clinical data mature favorably creates a potentially powerful re-rating setup.
The next several weeks could provide important answers.
Accumulating under .90.
$CATX $LNTH
3 replies
